Stoke Therapeutics, Inc. (NASDAQ:STOK) Forecasted to Post FY2028 Earnings of $0.15 Per Share

Stoke Therapeutics, Inc. (NASDAQ:STOK) – HC Wainwright reduced their FY2028 EPS estimates for Stoke Therapeutics in a research report issued to clients and investors on Thursday, August 8th. HC Wainwright analyst A. Fein now anticipates that the company will earn $0.15 per share for the year, down from their previous estimate of $0.17. HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.37) per share.

A number of other research firms have also recently weighed in on STOK. Canaccord Genuity Group decreased their price objective on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Thursday. Finally, Wedbush reiterated an “outperform” rating and issued a $17.00 price target on shares of Stoke Therapeutics in a research note on Thursday, July 11th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK traded down $0.04 on Friday, hitting $14.10. The company had a trading volume of 34,486 shares, compared to its average volume of 855,040. Stoke Therapeutics has a 12-month low of $3.35 and a 12-month high of $17.58. The business has a 50 day moving average of $14.48 and a two-hundred day moving average of $11.16.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.03. The firm had revenue of $4.22 million during the quarter, compared to analyst estimates of $3.33 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Redmile Group LLC boosted its holdings in Stoke Therapeutics by 93.2% in the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock valued at $68,486,000 after purchasing an additional 2,447,543 shares during the period. Lynx1 Capital Management LP lifted its holdings in shares of Stoke Therapeutics by 25.0% during the 1st quarter. Lynx1 Capital Management LP now owns 3,696,820 shares of the company’s stock worth $49,907,000 after acquiring an additional 739,902 shares during the period. Baker BROS. Advisors LP raised its position in Stoke Therapeutics by 65.9% in the first quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock worth $45,474,000 after purchasing an additional 1,338,309 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Stoke Therapeutics by 4.1% during the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock valued at $23,160,000 after purchasing an additional 67,052 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in Stoke Therapeutics in the 2nd quarter valued at about $19,835,000.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $13.75, for a total value of $137,500.00. Following the transaction, the insider now directly owns 2,485 shares of the company’s stock, valued at approximately $34,168.75. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 11.30% of the stock is owned by corporate insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.